

LIFE SCIENCES MARKET INTEL REPORT



CHECK OUT OUR WEBSITE:

WWW.GFORCELIFESCIENCES.COM

GFORCE QUICK INSIGHTS

\$22B

projected 2025 Venture Capital investment into biotech (vs. \$24.7B in 2024 and \$27B in 2021) ^

86%

of firms plan to hire for AI-focused roles \$

79%

have created new job titles for AI functions \$

75%

increased budget for AI talent \$

HOW IS AI IMPACTING COLLABORATION?

1

73% OF EMPLOYEES ARE MORE PRODUCTIVE WHEN WORKING TOGETHER*

2

72% ARE ENABLING EASIER REAL-TIME COLLABORATION*

3

65% ARE PROMPTING MORE CO-WORKER OUTREACH FOR HELP *

Sources:

^ Ashwin Singhania

\$ 24 Seven

• Express Employment Professionals-Harris Poll

2026 OUTLOOK

2026 BIOTECH OUTLOOK:

Expect transformative period driven by AI, digital tech, and increased M&A as big pharma seeks innovation, with growth expected in precision oncology (like CAR-T), cell/gene therapies, and cardiometabolic treatments, all supported by improved financing and a shift towards personalized, data-driven medicine despite lingering policy uncertainty.

2026 PHARMA OUTLOOK:

Likely to see accelerated growth driven by precision medicine (cell/gene therapies, ADCs, personalized approaches), significant AI integration in R&D and marketing, and evolving commercial strategies focused on human-machine collaboration, targeted patient engagement, and data-driven storytelling, despite ongoing pressures from payers and regulators.

2026 MEDTECH OUTLOOK:

Look for strong growth driven by AI, advanced diagnostics, personalized medicine, and at-home care, with increased M&A activity and venture capital funding, especially in cardiology, orthopedics, and neurostimulation. Key themes include AI integration for R&D and decision support, consumer-driven trends (home care, digital health), and a focus on efficiency and resilience, while navigating persistent challenges like supply chain issues and evolving regulatory landscapes.